← feed

Is NCT03220165 results overdue?

Yes — results are overdue. Primary completion was 2017-09-03; the FDAAA-801 reporting deadline (2018-09-03) passed 2848 days ago and no results are posted on ClinicalTrials.gov.

Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196

NCT IDNCT03220165 ↗
SponsorMadrigal Pharmaceuticals, Inc. (INDUSTRY)
Public issuerMADRIGAL PHARMACEUTICALS, INC. — MDGL (CIK 0001157601) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-09-03 (ACTUAL)
Reporting deadline2018-09-03 (completion + 365d)
Days overdue2848
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 0002f7d712b0397f… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03220165. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →